NasdaqGM:RAPTBiotechs
GSK Buyout Turns Volatile RAPT Into Food Allergy Cash-Out Story
GSK has signed a definitive agreement to acquire RAPT Therapeutics (NasdaqGM:RAPT).
The deal centers on ozureprubart, a long acting anti-IgE antibody in Phase IIb trials for food allergy prophylaxis.
The transaction brings a food allergy candidate into GSK’s immunology and inflammation portfolio.
RAPT Therapeutics, trading at $57.63, has recently seen very large 1 year returns and strong short term moves, with the share price up 64.2% over the past week and 60.8% over the past month. Year...